T1	CHEM 75 89	DAPAGLIFLOZINA
#1	AnnotatorNotes T1	C2353951; dapagliflozin; Organic Chemical · Pharmacologic Substance
T2	CHEM 91 110	INHIBIDOR DE SGLT-2
#2	AnnotatorNotes T2	C3665045; Sodium-Glucose Transporter Inhibitors; Molecular Function
T3	DISO 179 188	DM TIPO 1
#3	AnnotatorNotes T3	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome
T4	DISO 211 219	Diabetes
#4	AnnotatorNotes T4	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T5	DISO 245 260	Diabetes tipo 1
#5	AnnotatorNotes T5	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome
T6	PROC 545 558	procedimiento
#6	AnnotatorNotes T6	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T7	PROC 588 599	diagnóstico
#7	AnnotatorNotes T7	C0011900; Diagnosis; Diagnostic Procedure
T8	DISO 603 612	DM tipo 1
#8	AnnotatorNotes T8	C0011854; Diabetes Mellitus, Insulin-Dependent; Disease or Syndrome
T9	DISO 614 616	DM
#9	AnnotatorNotes T9	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T10	PROC 617 630	diagnosticada
#10	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	DISO 675 684	sobrepeso
#11	AnnotatorNotes T11	C0497406; Overweight; Finding
T12	DISO 687 689	DM
#12	AnnotatorNotes T12	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T13	PROC 690 703	diagnosticada
#13	AnnotatorNotes T13	C0011900; Diagnosis; Diagnostic Procedure
T14	DISO 729 754	autoinmunidad pancreática
T15	PROC 769 780	Tratamiento
#14	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	CHEM 804 812	insulina
#15	AnnotatorNotes T16	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T17	CHEM 841 857	insulina Detemir
#16	AnnotatorNotes T17	C0537270; insulin detemir; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T18	CHEM 902 928	análogo de insulina rápida
T19	PROC 932 960	infusión subcutánea continua
T20	PROC 1237 1261	consentimiento informado
#17	AnnotatorNotes T20	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T21	PROC 1387 1405	exploración física
#18	AnnotatorNotes T21	C0031809; Physical Examination; Health Care Activity
T22	PROC 1442 1459	análisis clínicos
#19	AnnotatorNotes T22	C0376583; Clinical Laboratory Techniques; Health Care Activity
T23	DISO 1562 1573	Hepatopatía
#20	AnnotatorNotes T23	C0023895; Liver diseases; Disease or Syndrome
T24	DISO 1590 1617	enfermedad hepática crónica
T25	PROC 1638 1665	pruebas de función hepática
#21	AnnotatorNotes T25	C0023901; Liver Function Tests; Laboratory Procedure
T26	PROC 1720 1724	MDRD
#22	AnnotatorNotes T26	C1980036; Creatinine-based formula (MDRD); Laboratory Procedure
T27	PROC 1677 1680	GGT
#23	AnnotatorNotes T27	C0202035; Gamma glutamyl transferase measurement; Laboratory Procedure
T28	DISO 1699 1718	Insuficiencia renal
#24	AnnotatorNotes T28	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T29	DISO 1742 1775	Infecciones urinarias o micóticas
T30	DISO 1809 1825	cáncer de vejiga
#25	AnnotatorNotes T30	C0005684; Malignant neoplasm of urinary bladder; Neoplastic Process
T31	DISO 1830 1876	Alteraciones del equilibrio hidroelectrolítico
T32	DISO 1878 1895	diabetes insípida
#26	AnnotatorNotes T32	C0011848; Diabetes Insipidus; Disease or Syndrome
T33	DISO 1897 1902	SIADH
#27	AnnotatorNotes T33	C0021141; Inappropriate ADH Syndrome; Disease or Syndrome
T34	DISO 1904 1917	hiponatremias
#28	AnnotatorNotes T34	C0020625; Hyponatremia; Disease or Syndrome
T35	PROC 1923 1934	Tratamiento
#29	AnnotatorNotes T35	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T36	CHEM 1939 1956	diuréticos de asa
#30	AnnotatorNotes T36	C0354100; Loop Diuretics; Pharmacologic Substance
T37	CHEM 1987 2011	fármaco en investigación
#31	AnnotatorNotes T37	C0013230; Investigational New Drugs; Pharmacologic Substance
T38	CHEM 2023 2052	antivirales de acción directa
#32	AnnotatorNotes T38	C3653501; DIRECT ACTING ANTIVIRALS; Pharmacologic Substance
T39	CHEM 2104 2111	fármaco
#33	AnnotatorNotes T39	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T40	PROC 59 70	TRATAMIENTO
#34	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	PROC 409 433	consentimiento informado
#35	AnnotatorNotes T41	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T42	PROC 439 471	Consentimiento informado escrito
#36	AnnotatorNotes T42	C0811741; Obtain informed written consent; Health Care Activity
T43	ANAT 743 754	pancreática
#37	AnnotatorNotes T43	C0030274; Pancreas; Body Part, Organ, or Organ Component | C1278931; Entire pancreas; Body Part, Organ, or Organ Component
T44	PROC 818 829	inyecciones
#38	AnnotatorNotes T44	C1533685; Injection procedure; Therapeutic or Preventive Procedure
T45	CHEM 860 868	Glargina
T46	PROC 873 884	inyecciones
#39	AnnotatorNotes T46	C1533685; Injection procedure; Therapeutic or Preventive Procedure
T47	PROC 1025 1030	HbA1c
#40	AnnotatorNotes T47	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T48	ANAT 1601 1609	hepática
#41	AnnotatorNotes T48	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T49	ANAT 1657 1665	hepática
#42	AnnotatorNotes T49	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T50	PROC 1667 1670	AST
#43	AnnotatorNotes T50	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T51	PROC 1672 1675	ALT
#44	AnnotatorNotes T51	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T52	PROC 1682 1693	Bilirrubina
#45	AnnotatorNotes T52	C0863174; Blood bilirubin measurement; Laboratory Procedure
T53	ANAT 1713 1718	renal
#46	AnnotatorNotes T53	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T54	ANAT 1754 1763	urinarias
#47	AnnotatorNotes T54	C1508753; Urinary system; Body System
T55	ANAT 1819 1825	vejiga
#48	AnnotatorNotes T55	C0005682; Urinary Bladder; Body Part, Organ, or Organ Component
T56	PROC 2085 2111	administración del fármaco
#49	AnnotatorNotes T56	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T57	Date 12 16	2015
T58	PHYS 121 139	CONTROL METABÓLICO
#50	AnnotatorNotes T58	C1513158; Metabolic Control; Molecular Function
T59	LIVB 165 174	PACIENTES
#51	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 291 298	Hombres
#52	AnnotatorNotes T60	C0025266; Male population group; Population Group
T61	LIVB 301 308	mujeres
#53	AnnotatorNotes T61	C0043210; Woman; Population Group
T62	Age 333 351	entre 18 y 55 años
T63	LIVB 574 583	Pacientes
#54	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Age 644 651	30 años
T65	Neg_cue 663 674	ausencia de
T66	Age 717 724	45 años
T67	Dose 785 800	múltiples dosis
T68	Frequency 830 837	diarias
T69	Time 885 898	preprandiales
T71	Route 941 951	subcutánea
#55	AnnotatorNotes T71	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
T72	Duration 961 990	al menos durante los 12 meses
T73	Duration 1105 1116	los 6 meses
T74	Duration 1162 1182	un mínimo de 3 meses
T75	Neg_cue 1213 1229	Incapacidad para
T76	Neg_cue 1268 1279	ausencia de
T77	PHYS 1306 1314	Embarazo
#56	AnnotatorNotes T77	C0032961; Pregnancy; Organism Function
T78	PHYS 1317 1326	lactancia
#57	AnnotatorNotes T78	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T80	LIVB 1350 1362	investigador
#58	AnnotatorNotes T80	C0035173; Research Personnel; Professional or Occupational Group
T81	PHYS 1486 1496	cognitivos
#59	AnnotatorNotes T81	C0009240; Cognition; Mental Process
T83	Duration 1610 1617	crónica
#60	AnnotatorNotes T83	C0205191; chronic; Temporal Concept
T85	PHYS 1649 1665	función hepática
#61	AnnotatorNotes T85	C0232741; Liver function; Organ or Tissue Function
T86	LIVB 1766 1775	micóticas
#62	AnnotatorNotes T86	C0016832; Fungi; Fungus
T87	PHYS 1847 1876	equilibrio hidroelectrolítico
#63	AnnotatorNotes T87	C0043064; Water-Electrolyte Balance; Organism Function
T88	Duration 2057 2068	los 60 días
T90	Dose 814 829	1-2 inyecciones
T91	Dose 871 884	3 inyecciones
T70	LIVB 1283 1300	responsable legal
#64	AnnotatorNotes T70	C4288823; Legal Representative for the Study; Human
T79	DISO 1620 1665	alteración en las pruebas de función hepática
#65	AnnotatorNotes T79	C0151766; Liver function tests abnormal; Finding [ICD-10: R94.5]
A1	Assertion T11 Negated
A2	Assertion T20 Negated
A3	Assertion T70 Negated
A4	Status T24 History_of
A5	Status T79 History_of
A6	Status T30 History_of
A7	Status T37 History_of
A8	Status T38 History_of
#66	AnnotatorNotes T45	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Pharmacologic Substance · 
#67	AnnotatorNotes T19	C0393124; Continuous subcutaneous infusion of insulin; Therapeutic or Preventive Procedure 
#68	AnnotatorNotes T24	C0341439; Chronic liver disease; Disease or Syndrome
T82	Neg_cue 1527 1535	pudieran
T84	Observation 1536 1557	influir negativamente
A9	Assertion T84 Speculated
R1	Negation Arg1:T65 Arg2:T11	
R2	Negation Arg1:T75 Arg2:T20	
R3	Negation Arg1:T76 Arg2:T70	
R4	Negation Arg1:T82 Arg2:T84	
R5	Used_for Arg1:T1 Arg2:T40	
R6	Used_for Arg1:T2 Arg2:T40	
R8	Experiences Arg1:T59 Arg2:T3	
R9	Experiences Arg1:T59 Arg2:T40	
R10	Experiences Arg1:T59 Arg2:T58	
R11	Has_Age Arg1:T60 Arg2:T62	
R12	Has_Age Arg1:T61 Arg2:T62	
R13	Overlap Arg1:T41 Arg2:T62	
T89	CONC 483 486	ICH
#69	AnnotatorNotes T89	C4684685; ICH Common Technical Document; Intellectual Product
T92	CONC 487 490	GCP
#70	AnnotatorNotes T92	C5235445; GCP Adherence Statement; Intellectual Product
R14	Before Arg1:T42 Arg2:T6	
R15	Experiences Arg1:T63 Arg2:T8	
R16	Experiences Arg1:T63 Arg2:T9	
R17	Before Arg1:T8 Arg2:T64	
R18	Before Arg1:T9 Arg2:T64	
R19	Before Arg1:T10 Arg2:T64	
R20	Before Arg1:T7 Arg2:T64	
R21	Overlap Arg1:T8 Arg2:T11	
R22	Overlap Arg1:T9 Arg2:T11	
R23	Before Arg1:T12 Arg2:T66	
R24	Has_Age Arg1:T63 Arg2:T66	
R25	Has_Age Arg1:T63 Arg2:T64	
R26	Before Arg1:T13 Arg2:T66	
R27	Overlap Arg1:T12 Arg2:T14	
R28	Location_of Arg1:T43 Arg2:T14	
T93	Result_or_Value 755 763	positiva
#71	AnnotatorNotes T93	C1446409; Positive; Finding
R29	Has_Result_or_Value Arg1:T14 Arg2:T93	
R30	Experiences Arg1:T63 Arg2:T14	
R31	Experiences Arg1:T63 Arg2:T11	
R32	Experiences Arg1:T63 Arg2:T12	
R33	Has_Dose_or_Strength Arg1:T16 Arg2:T67	
R34	Has_Dose_or_Strength Arg1:T16 Arg2:T90	
R35	Used_for Arg1:T16 Arg2:T15	
R36	Used_for Arg1:T16 Arg2:T44	
R37	Has_Frequency Arg1:T16 Arg2:T68	
R38	Has_Dose_or_Strength Arg1:T17 Arg2:T90	
R39	Used_for Arg1:T45 Arg2:T44	
R40	Used_for Arg1:T17 Arg2:T44	
R41	Has_Dose_or_Strength Arg1:T45 Arg2:T90	
R42	Has_Frequency Arg1:T17 Arg2:T68	
R43	Has_Frequency Arg1:T45 Arg2:T68	
R44	Overlap Arg1:T18 Arg2:T69	
R45	Used_for Arg1:T18 Arg2:T46	
R46	Has_Dose_or_Strength Arg1:T18 Arg2:T91	
#72	AnnotatorNotes T69	C1550738; ante cibus; Temporal Concept
R47	Used_for Arg1:T16 Arg2:T19	
R48	Has_Route_or_Mode Arg1:T16 Arg2:T71	
R49	Has_Duration_or_Interval Arg1:T16 Arg2:T72	
T94	CONC 1002 1020	inicio del estudio
#73	AnnotatorNotes T94	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R50	Before Arg1:T19 Arg2:T94	
R51	Combined_with Arg1:T17 Arg2:T18	
R52	Combined_with Arg1:T45 Arg2:T18	
T95	Result_or_Value 1034 1045	mayor de 7%
R53	Has_Result_or_Value Arg1:T47 Arg2:T95	
T96	Quantifier_or_Qualifier 1049 1077	al menos dos determinaciones
R54	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T96	
T97	Quantifier_or_Qualifier 1078 1090	consecutivas
#74	AnnotatorNotes T97		C1707491; Consecutive; Qualitative Concept
R55	Has_Quantifier_or_Qualifier Arg1:T47 Arg2:T97	
R56	Has_Duration_or_Interval Arg1:T47 Arg2:T74	
T98	CONC 1128 1146	inicio del estudio
#75	AnnotatorNotes T98	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R57	Overlap Arg1:T47 Arg2:T73	
R58	Before Arg1:T47 Arg2:T98	
T99	Observation 1407 1459	anomalías en los resultados de los análisis clínicos
#76	AnnotatorNotes T99	C3648370; laboratory tests nonspecific abnormal findings; Finding
T100	Observation 1371 1405	hallazgos en la exploración física
#77	AnnotatorNotes T100	C0311392; Physical findings; Finding
R59	Overlap Arg1:T100 Arg2:T21	
R60	Overlap Arg1:T99 Arg2:T22	
R61	Before Arg1:T100 Arg2:T84	
R62	Before Arg1:T99 Arg2:T84	
T101	Observation 1468 1522	factores médicos, cognitivos, sociales o psicosociales
R63	Before Arg1:T101 Arg2:T84	
R64	Location_of Arg1:T48 Arg2:T23	
R65	Location_of Arg1:T48 Arg2:T24	
R66	Has_Duration_or_Interval Arg1:T24 Arg2:T83	
R70	Location_of Arg1:T49 Arg2:T85	
R71	Location_of Arg1:T49 Arg2:T79	
R72	Location_of Arg1:T49 Arg2:T50	
R73	Location_of Arg1:T49 Arg2:T51	
R74	Location_of Arg1:T49 Arg2:T27	
R75	Location_of Arg1:T49 Arg2:T52	
T102	Result_or_Value 1725 1736	< 60 ml/min
R84	Has_Result_or_Value Arg1:T26 Arg2:T102	
R85	Location_of Arg1:T53 Arg2:T28	
R87	Causes Arg1:T86 Arg2:T29	
T103	Quantifier_or_Qualifier 1776 1789	de repetición
#78	AnnotatorNotes T103	C2945760; Recurrent; Temporal Concept
R88	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T103	
#79	AnnotatorNotes T29	C0026946; Mycoses; Disease or Syndrome | C0042029; Urinary tract infection; Disease or Syndrome
R89	Location_of Arg1:T55 Arg2:T30	
#80	AnnotatorNotes T31	C0342579; Electrolyte imbalance; Pathologic Function
R94	Used_for Arg1:T36 Arg2:T35	
R95	Overlap Arg1:T37 Arg2:T88	
R96	Overlap Arg1:T38 Arg2:T88	
R97	Before Arg1:T37 Arg2:T56	
R98	Before Arg1:T38 Arg2:T56	
R99	Used_for Arg1:T39 Arg2:T56	
R7	Before Arg1:T15 Arg2:T94	
#81	AnnotatorNotes T18	C3653577; Insulins and analogues for injection, fast-acting; Amino Acid, Peptide, or Protein · Pharmacologic Substance · Hormone 
A10	Experiencer T59 Patient
A11	Experiencer T61 Patient
A12	Experiencer T60 Patient
A13	Experiencer T63 Patient
A14	Experiencer T70 Other
A15	Experiencer T80 Other
A16	Assertion T100 Hypothetical
A17	Assertion T99 Hypothetical
A18	Assertion T101 Hypothetical
